D. E. Shaw & Co. Inc. Sells 106,200 Shares of Quanterix Co. (NASDAQ:QTRX)

D. E. Shaw & Co. Inc. lessened its holdings in shares of Quanterix Co. (NASDAQ:QTRX) by 56.4% in the fourth quarter, according to its most recent 13F filing with the Securities and Exchange Commission. The institutional investor owned 82,192 shares of the company’s stock after selling 106,200 shares during the quarter. D. E. Shaw & Co. Inc. owned 0.21% of Quanterix worth $874,000 as of its most recent SEC filing.

Other hedge funds have also recently bought and sold shares of the company. Resona Asset Management Co. Ltd. purchased a new position in shares of Quanterix in the 4th quarter worth about $55,000. Tower Research Capital LLC TRC increased its position in shares of Quanterix by 219.1% in the fourth quarter. Tower Research Capital LLC TRC now owns 5,702 shares of the company’s stock worth $61,000 after purchasing an additional 3,915 shares during the last quarter. KLP Kapitalforvaltning AS bought a new position in shares of Quanterix in the fourth quarter worth approximately $66,000. Canada Pension Plan Investment Board boosted its stake in Quanterix by 64.5% in the fourth quarter. Canada Pension Plan Investment Board now owns 10,200 shares of the company’s stock worth $108,000 after buying an additional 4,000 shares in the last quarter. Finally, Cetera Investment Advisers purchased a new stake in Quanterix in the fourth quarter worth approximately $108,000. 86.48% of the stock is owned by hedge funds and other institutional investors.

Analysts Set New Price Targets

A number of analysts have recently weighed in on the company. Scotiabank reissued an “outperform” rating on shares of Quanterix in a research note on Tuesday, March 25th. Leerink Partners restated a “market perform” rating and set a $8.00 price target (down from $12.00) on shares of Quanterix in a report on Wednesday, April 30th. Canaccord Genuity Group reduced their price target on Quanterix from $15.00 to $12.00 and set a “buy” rating for the company in a report on Tuesday, May 13th. Wall Street Zen downgraded Quanterix from a “hold” rating to a “sell” rating in a report on Thursday. Finally, Leerink Partnrs cut Quanterix from a “strong-buy” rating to a “hold” rating in a research report on Wednesday, April 30th. One investment analyst has rated the stock with a sell rating, three have issued a hold rating and three have assigned a buy rating to the company’s stock. According to MarketBeat, the company currently has an average rating of “Hold” and a consensus price target of $15.60.

Quanterix Stock Up 0.4%

QTRX stock opened at $4.85 on Friday. The business’s 50-day moving average price is $5.64 and its 200-day moving average price is $8.53. Quanterix Co. has a twelve month low of $4.05 and a twelve month high of $19.18. The stock has a market cap of $188.32 million, a P/E ratio of -4.58 and a beta of 1.12.

Quanterix (NASDAQ:QTRX) last released its quarterly earnings data on Monday, May 12th. The company reported ($0.53) earnings per share (EPS) for the quarter, topping analysts’ consensus estimates of ($0.69) by $0.16. The business had revenue of $30.33 million for the quarter, compared to the consensus estimate of $28.27 million. Quanterix had a negative return on equity of 11.74% and a negative net margin of 30.12%. On average, equities research analysts expect that Quanterix Co. will post -0.98 earnings per share for the current fiscal year.

Quanterix Company Profile

Quanterix Corporation, a life sciences company, engages in development and marketing of digital immunoassay platforms that advances precision health for life sciences research and diagnostics in North America, Europe, the Middle East, Africa, and the Asia Pacific regions. The company offers HD-X instrument, a protein detection platform; and SR-X instrument that enables researchers to apply Simoa detection in an expanded range of applications.